1258 related articles for article (PubMed ID: 33155660)
81. Signal transducer and activator of transcription 5a inhibited by pimozide may regulate survival of goat mammary gland epithelial cells by regulating parathyroid hormone-related protein.
Li H; Zheng H; Sun Y; Yu Q; Li L
Gene; 2014 Nov; 551(2):279-89. PubMed ID: 25194899
[TBL] [Abstract][Full Text] [Related]
82. Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter.
Brockman JL; Schuler LA
Mol Cell Endocrinol; 2005 Jul; 239(1-2):45-53. PubMed ID: 15885880
[TBL] [Abstract][Full Text] [Related]
83. Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications.
Biagetti B; Simò R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681905
[TBL] [Abstract][Full Text] [Related]
84. MR volumetry for monitoring intramuscular bromocriptine treatment in macroprolactinomas.
Benesch H; Felber SR; Finkenstedt G; Kremser C; Stockhammer G; Aichner FT
J Comput Assist Tomogr; 1995; 19(6):866-70. PubMed ID: 8537517
[TBL] [Abstract][Full Text] [Related]
85. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
86. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.
Caccavelli L; Feron F; Morange I; Rouer E; Benarous R; Dewailly D; Jaquet P; Kordon C; Enjalbert A
Neuroendocrinology; 1994 Sep; 60(3):314-22. PubMed ID: 7969790
[TBL] [Abstract][Full Text] [Related]
87. [Long-term bromocriptine treatment of giant prolactinoma: report of a case].
Mashio Y; Beniko M; Ikota A; Mizumoto H; Sato S; Yamaguchi O; Suzuki S; Tashiro T; Ikota T
Nihon Naika Gakkai Zasshi; 1989 Dec; 78(12):1785-6. PubMed ID: 2625603
[No Abstract] [Full Text] [Related]
88. Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma.
Hu B; Mao Z; Jiang X; He D; Wang Z; Wang X; Zhu Y; Wang H
Brain Res; 2018 Nov; 1698():204-212. PubMed ID: 30055965
[TBL] [Abstract][Full Text] [Related]
89. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Jia H; Ren W; Feng Y; Wei T; Guo M; Guo J; Zhao J; Song X; Wang M; Zhao T; Wang H; Feng Z; Tian Z
Int J Oncol; 2018 Sep; 53(3):949-960. PubMed ID: 30015838
[TBL] [Abstract][Full Text] [Related]
90. Prolactinomas in infertile women: clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine.
Hajder M; Hajder E; Dervisefendic M; Samardzic R; Alic E
Med Arch; 2013; 67(3):181-4. PubMed ID: 23848038
[TBL] [Abstract][Full Text] [Related]
91. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
[TBL] [Abstract][Full Text] [Related]
92. Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development.
Kuchenbauer F; Theodoropoulou M; Hopfner U; Stalla J; Renner U; Tonn JC; Low MJ; Arzt E; Stalla GK; Páez-Pereda M
Mol Cell Endocrinol; 2003 Sep; 207(1-2):13-20. PubMed ID: 12972179
[TBL] [Abstract][Full Text] [Related]
93. Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Jones TH; Figueroa CD; Smith CM; Bhoola KD
Agents Actions Suppl; 1992; 38 ( Pt 2)():175-82. PubMed ID: 1462825
[TBL] [Abstract][Full Text] [Related]
94. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
95. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
96. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
[TBL] [Abstract][Full Text] [Related]
97. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
Chattopadhyay A; Bhansali A; Masoodi SR
Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
[TBL] [Abstract][Full Text] [Related]
98. Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines.
Wang X; Du Q; Mao Z; Fan X; Hu B; Wang Z; Chen Z; Jiang X; Wang Z; Lei N; Wang H; Zhu Y
Oncotarget; 2017 Jul; 8(28):45874-45887. PubMed ID: 28501857
[TBL] [Abstract][Full Text] [Related]
99. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
[TBL] [Abstract][Full Text] [Related]
100. Bromocriptine treatment of prolactinoma restores growth hormone secretion and causes catch-up growth in a prepubertal child.
Sakazume S; Obata K; Takahashi E; Yoshino A; Murakami N; Sakuta R; Murai T; Nagai T
Eur J Pediatr; 2004 Aug; 163(8):472-4. PubMed ID: 15160292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
